No Data
No Data
Sino Biopharmaceutical Gets Marketing Go-Ahead for Lung Cancer Drug in China
Sino Biopharmaceutical (HKG:1177) has obtained marketing approval for its Envonalkib tablets from China's National Medical Products Administration, a Wednesday filing by the pharmaceutical company wit
Sino Biopharm (01177.HK): Type 1 innovative drug Envonalkib (TQ-B3139) in citrate form has been approved for listing.
Sino Biopharmaceutical announced on June 19th that the group's independently developed class 1 innovative drug, envonalkib (TQ-B3139) (trade name: Anluoqing), which is a capsule of citrate enfonidacil, has been granted approval for marketing by the China National Medical Products Administration. It is used for the treatment of local advanced or metastatic non-small cell lung cancer (NSCLC) patients who are ALK-positive but have not received an ALK inhibitor. Enfonidacil is a new type of ALK inhibitor independently developed by the group, and this indication is for first-line treatment of ALK-positive NSCLC.
Express News | Sino Biopharmaceutical - Envonalkib (Tq-B3139) Obtained Approval for Marketing From Nmpa of China
First Shanghai maintains a "buy" rating for Sino Biopharm (01177) with a target price of HKD 3.25.
First Shanghai expects that innovative products in 2025 will account for 47% of Sino Biopharm's (01177) revenue.
Sino Biopharm Trustee Purchases 15.8 Million Shares Under Incentive Scheme
The trustee of Sino Biopharmaceutical (HKG:1177) unit Chia Tai Tianqing purchased 15.8 million shares between June 5 and June 13 under a share award scheme, according to a Thursday filing with the Hon
Sino Biopharm (01177.HK): SDIC Tianqing Pharmaceutical Co., Ltd. Incentive Plan Buys Shares
Sino Biopharm (01177.HK) announced that on May 7, 2024, China Biopharmaceuticals Co., Ltd. made an announcement on the implementation of equity incentive plan for its subsidiary, Zhejiang Jingxin Tianqing Pharmaceutical Group Co., Ltd. ("Jingxin Tianqing"). From June 5, 2024 to June 13, 2024, the trustee purchased a total of 15.842 million shares of the company on the market according to the terms and conditions of the share incentive plan, which will be used for subsequent implementation of share incentives for selected participants.
No Data